Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11  years

Rituximab is efficacious in myelin-associated glycoprotein (MAG) polyneuropathy, but the question on timing of retreatments is open. We studied 21 anti-MAG polyneuropathy patients who responded to a first cycle of rituximab, were followed-up for an average of 11.2  years, and were retreated only when relapsing. Baseline serum B-cell-activating factor (BAFF) levels were measured.Clinical improvements lasted on average 6 years, and as many as 71% of the patients resulted long-lasting responders. Severity of disease and high serum BAFF levels (cut-off ≥860  pg/mL for relapse risk) at onset seemed to predict worse prognosis.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Tags: Short communication Source Type: research